Connecticut AG William Tong and a bipartisan coalition of 35 attorneys general urge Meta to enforce policies against misleading AI weight loss ads, prohibit non-FDA approved drugs, and enhance AI content labeling.

enforcement action United States / CT enforcement 9/10

Government · Connecticut Attorney General

Attorney General William Tong and a coalition of 35 state attorneys general have called on Meta to strengthen its enforcement of policies against misleading AI-generated weight loss ads on Instagram and Facebook. They specifically request Meta to restrict ads to only FDA-approved prescription drugs, require clear disclosure of risks, prohibit AI-generated content in weight loss drug ads, and improve AI content labeling and detection. The AGs highlight the use of deceptive AI-generated images and fake spokespeople promoting non-FDA approved GLP-1 drugs.

Effective date

2025-12-23

Action required

Meta must enforce its existing policies, restrict prescription drug ads to FDA-approved products, require risk disclosures, prohibit AI-generated content in weight loss ads, and implement better tools for AI content labeling and detection.

Binding status

advisory

Governing body

Connecticut Attorney General

Direction

restrictive

Innovation impact

constraining

Enforcement details

Agency

Connecticut Attorney General and 35 bipartisan attorneys general

Compliance requirements

Required disclosures

Content promoting weight loss products must clearly disclose the risks and potential side effects.
Advertisers are supposed to share information about the medical effectiveness and affordability of drugs (Meta's existing policy).

Prohibited practices

Selling non-FDA approved weight loss drugs through deceptive, AI-generated ads.
Misleading health advertising (Meta's existing policy).
Ads that push a 'perfect' body type or foster unhealthy body images (Meta's existing policy).
Weight loss drug ads that use AI-generated content (requested by AGs).
Targeting ads for prescription drugs to non-adults (Meta's existing policy).

Transparency requirements

Require transparency in advertising.
Label AI-generated content more clearly.

AI technologies

generative aisynthetic media

Affected industries

advertisinghealthcaretechnology

Affected roles

compliance officerproduct managerrisk manager

Linked intelligence briefs

AG Tong Leads Coalition Urging Meta to Curb Misleading AI Weight Loss Ads

Connecticut Attorney General William Tong and a coalition of 35 other bipartisan attorneys general have called on Meta to enhance the enforcement of its existing policies concerning pharmaceutical and wellness advertisements on Instagram and Facebook [1]. The coalition specifically requested Meta to prevent misleading AI-generated content in weight loss ads and restrict the promotion of non-FDA approved GLP-1 drugs. They urged Meta to require risk disclosures, prohibit AI-generated content in weight loss ads, and develop better tools for AI content detection and labeling [2].

"Selling non-FDA approved weight loss drugs through deceptive, AI-generated ads is dangerous and irresponsible. Meta’s own policies prohibit misleading health advertising, yet these ads continue to run. We’re calling on Meta to enforce its own rules, require transparency, and stop putting consumers at risk."

Enriched 2026-04-29

Stay informed

Get daily intelligence briefs on this and related regulatory developments.

Start 14-day trial

Important — about this brief

This brief is published by AIGI as a regulatory intelligence service. It contains general information about AI laws, regulations, enforcement actions, and policy signals across jurisdictions. It is not legal, compliance, audit, or risk-management advice; it does not establish an attorney-client, advisory, or fiduciary relationship; and it should not be relied upon as a substitute for professional counsel applied to specific facts and circumstances. Where the brief identifies “Issues for Review,” those are observations of questions a reader in a particular role might raise with their own legal, compliance, or risk function — not recommendations to act. AIGI expressly disclaims liability for actions taken or not taken in reliance on this brief. Subscribers in regulated industries should consult licensed professionals authorized to practice in their jurisdiction.

Full disclosures →